The Pfizer and Chiesi-backed gene therapy developer plans to use the IPO proceeds to advance treatments for Fabry disease, cystic fibrosis and ophthalmological diseases.

US-based genetic medicine developer 4D Molecular Therapeutics filed to raise $100m in an initial public offering on Monday that will enable pharmaceutical companies Pfizer and Chiesi Group to exit. 4D is developing gene therapies and will put part of the IPO proceeds toward a phase 1/2 clinical trial for 4D-310, a drug candidate for Fabry…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.